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Abstract
Background—The pathology of pediatric severe therapy-resistant asthma (STRA) is little
understood.
Objectives—We hypothesized that STRA in children is characterized by airway eosinophilia
and mast cell inflammation and is driven by the TH2 cytokines IL-4, IL-5, and IL-13.
Methods—Sixty-nine children (mean age, 11.8 years; interquartile range, 5.6-17.3 years; patients
with STRA, n = 53; control subjects, n = 16) underwent fiberoptic bronchoscopy, bronchoalveolar
lavage (BAL), and endobronchial biopsy. Airway inflammation, remodeling, and BAL fluid and
biopsy specimen TH2 cytokines were quantified. Children with STRA also underwent symptom
assessment (Asthma Control Test), spirometry, exhaled nitric oxide and induced sputum
evaluation.
Results—Children with STRA had significantly increased BAL fluid and biopsy specimen
eosinophil counts compared with those found in control subjects (BAL fluid, P < .001; biopsy
specimen, P < .01); within the STRA group, there was marked between-patient variability in
eosinophilia. Submucosal mast cell, neutrophil, and lymphocyte counts were similar in both
groups. Reticular basement membrane thickness and airway smooth muscle were increased in
patients with STRA compared with those found in control subjects (P < .0001 and P < .001,
respectively). There was no increase in BAL fluid IL-4, IL-5, or IL-13 levels in patients with
STRA compared with control subjects, and these cytokines were rarely detected in induced
sputum. Biopsy IL-5+ and IL-13+ cell counts were also not higher in patients with STRA
compared with those seen in control subjects. The subgroup (n = 15) of children with STRA with
detectable BAL fluid TH2 cytokines had significantly lower lung function than those with
undetectable BAL fluid TH2 cytokines.
Conclusions—STRA in children was characterized by remodeling and variable airway
eosinophil counts. However, unlike in adults, there was no neutrophilia, and despite the wide
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range in eosinophil counts, the TH2 mediators that are thought to drive allergic asthma were
mostly absent.
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The 5% of patients with asthma classified as severe consume more than 50% of health care
resources for the disease. Previous pediatric studies have investigated the pathology of
“difficult asthma”1,2 after a steroid trial and also mild-to-moderate asthma,3,4 but the
pathology of true severe therapy-resistant disease has been little studied. Children referred to
us for evaluation of symptoms refractory to high-dose conventional asthma therapy are
considered to have “problematic severe asthma.”5 This group comprises those with the
wrong diagnosis, asthma with comorbidity, difficult asthma, and severe therapy-resistant
asthma (STRA). They undergo detailed evaluation both at home and in the hospital.5,6
Those with difficult asthma in whom potentially reversible factors (persistent allergen
exposure, poor adherence, and poor inhaler technique) contributing to poor asthma control
are identified are excluded.5 Those remaining with genuine STRA undergo invasive testing
with bronchoscopy, bronchoalveolar lavage (BAL), and endobronchial biopsy to
characterize airway pathology and develop an individualized treatment plan.7
Previous studies have reported submucosal eosinophilia in pediatric patients with mild-to-
moderate asthma3,4 but not in children with problematic severe asthma.2 However, this
included patients with difficult asthma and subjects in whom bronchoscopy was performed
after a high-dose steroid trial. A further report in patients with difficult asthma has shown
increased epithelial eosinophil and neutrophil counts and higher BAL levels of IFN-γ in
children with persistent symptoms compared with those with good symptom control.8
However, there was no nonasthmatic control group and no assessment of basic asthma
management.
In summary, the basic mechanisms and airway pathology in children with true STRA are
unknown. Adult studies suggest that in many patients the pathobiology of severe asthma is
mediated by immune pathways driven by TH2-type CD4+ T cells, with signature cytokines
including IL-4, IL-5, and IL-13.9,10 Hence biological modifiers of TH2-type cytokines are a
rational strategy for developing new treatment approaches in adults.9 However, all studies to
date, whether in vivo experimental models or in vitro models, have been conducted with
adult animals11 or samples,12 respectively. Children with STRA are known to be markedly
atopic,13,14 and therefore we hypothesized that these children would also have eosinophilic
and mast cell inflammation and that childhood STRA would be characterized by increased
levels of the TH2 cytokines IL-4, IL-5, and IL-13. The aim of this study was to characterize
the pathology and mediators of inflammation and remodeling in patients with STRA.
METHODS
Subjects
Children aged 5 to 16 years referred to Royal Brompton Hospital with problematic severe
asthma between April 2005 and June 2009 were included.6 Definitions of poor control and
entry criteria were as follows:
1. persistent (most days for ≥3 months) chronic symptoms (which prompt use of
short-acting β2-agonists ≥3 times per week) of airway obstruction despite high
doses of inhaled corticosteroids (ICSs; ≥800 μg/d budesonide equivalent) and/or
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regular oral corticosteroids, long-acting β2-agonists, and current (or previous failed
trial of) montelukast OR
2. recurrent severe exacerbations requiring 1 or more admission to the intensive care
unit or 2 or more hospital admissions requiring intravenous medications or 2 or
more courses of oral corticosteroids in the past year despite therapy for persistent
symptoms as described in (1) above OR
3. at least 1 very sudden (≤6 hours) severe attack (requiring hospitalization) without
warning despite therapy for persistent symptoms, as described in (1) above.
Outpatient nurse-led assessments were performed to assess medication, dose, device and
technique, atopic status, and asthma understanding. A home and school visit was undertaken
to assess adherence, the environment, and any psychosocial issues. Evaluation of adherence
included prescription records, accessibility of medications, and whether medications were in
date and/or unwrapped; allergen sources, such as pets within the home; and environmental
tobacco smoke exposure (including cotinine measurements).
After assessment,6 those reclassified as having difficult asthma5 were excluded (Fig 1). The
remaining patients with STRA were further investigated. The study was approved by the
local research ethics committee, and all procedures were performed after obtaining written
informed parental consent and, where appropriate, child assent.
Nonasthmatic control subjects (aged 6-16 years) were either (1) undergoing a bronchoscopy
to investigate upper airway symptoms and agreed to extra research samples being taken or
(2) were undergoing general anesthesia for cardiac catheterization and agreed to have a
research bronchoscopy at the same time. They had no history of wheeze or lower airway
symptoms, and all were deemed sufficiently stable that the extra few minutes to take
research samples15 were permissible, as judged by an anesthetist independent of the study.
The clinical characteristics of control subjects are shown in Table E1 in this article’s Online
Repository at www.jacionline.org.
Investigations
All investigations were performed on the same day. None of the children had an
exacerbation at the time of bronchoscopy, and at least 2 weeks were required between the
last exacerbation and investigations. Details of investigations are given in the Methods
section in this article’s Online Repository at www.jacionline.org.
Atopic status—Atopy was defined as 1 or more positive specific IgE RAST (≥0.34 kU/L)
or 1 or more positive skin prick test results to aeroallergens.
Symptom control—Asthma control was assessed by using the Asthma Control Test16,17;
poor control was defined as a score of less than 20 of 25 (see Fig E1 in this article’s Online
Repository at www.jacionline.org).
Lung function—Spirometry and bronchodilator reversibility (BDR) defined as a greater
than 12% change from baseline FEV1 were measured according to American Thoracic
Society/European Thoracic Society guidelines.18,19
Exhaled nitric oxide—Exhaled nitric oxide measurements at a flow rate of 50 mL/s were
made with a chemiluminescence analyzer (NIOX; Aerocrine AB, Solna, Sweden) in
accordance with American Thoracic Society/European Thoracic Society guidelines.20
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Sputum induction and processing—Sputum induction was performed with 3.5%
saline (0.9% if postbronchodilator FEV1 was <65% of predicted value).21 Samples were
processed by adding 0.1% dithiothreitol (DTT). Supernatants were stored at −80°C. Samples
were considered adequate if 80% or fewer squamous cells and 400 or more inflammatory
cells were present and distinguishable.
Bronchoscopy, BAL, and endobronchial biopsy—Bronchoscopy, BAL, and
endobronchial biopsy were performed under general anesthesia, as previously described.22
BAL fluid was processed for cytology by the hospital cytopathology department.
Eosinophilia was defined as greater than 1.19%23 and neutrophilia as greater than 3.5%24 of
the total cell count. Paraffin-embedded biopsy specimens were cut and stained with
hematoxylin and eosin (H&E) to assess quality and adequate morphology and also to
quantify airway remodeling (reticular basement membrane [RBM] thickness,25 epithelial
shedding,4 and airway smooth muscle [ASM] mass26). Evaluable sections were also stained
for eosinophils (Congo red dye), neutrophils (neutrophil elastase), mast cells (mast cell
tryptase), and CD45+, CD4+, and CD8+ cells (for more information, see the Methods section
in this article’s Online Repository). All sections were coded, and inflammatory cells were
expressed per square millimeter of tissue.25
Induced sputum, BAL fluid, and biopsy specimen cytokine analysis—Cytokines
were quantified in BAL fluid and sputum supernatants by using the Luminex multiplex bead
analysis system. The premade 21-plex Luminex plate (Bio-Rad Laboratories, Hercules,
Calif) was used to assay levels of IL-1β, IL-4, IL-5, IL-8, IL-13, eotaxin, and IFN-γ. In
addition, the Cytometric Bead Array (CBA Human Inflammation kit; BD Biosciences,
PharMingen, San Diego, Calif) was used to quantify IL-5 and IL-13 (for more information,
see the Methods section in this article’s Online Repository).27 Endobronchial biopsy
specimens were stained for IL-5+ and IL-13+ cells by using immunohistochemistry, and
positive submucosal cells were quantified and expressed per square millimeter of tissue (for
more information, see the Methods section in this article’s Online Repository).
Additional investigations to exclude alternate diagnoses—All children in whom
BDR could not be demonstrated or who were nonatopic underwent high-resolution
computed tomographic chest scans to exclude diagnoses, such as bronchiectasis or
obliterative bronchiolitis. They also underwent blood tests to exclude rheumatologic
diseases and pH studies to exclude gastroesophageal reflux.
Statistical analysis
There are insufficient data to inform a power calculation for pediatric biopsy studies; adult
studies have reported that groups of 11 to 17 are sufficient.25 The sample size for control
subjects was opportunistic. Differences between groups were assessed by using the Mann-
Whitney U test. Associations were assessed with Spearman correlation. Intraobserver
repeatability was measured by calculating the coefficient of variation (CV) of 3
measurements of a section made on 3 occasions at least 3 days apart. Within-subject
variability was assessed based on the CV of counts from 3 or more biopsy specimens from
the same subject. Analysis was performed with the SPSS software, version 17 (SPSS, Inc,
Chicago, Ill). A P value of less than .05 was considered significant for between-group
comparisons, and a P value of less than .01 was considered significant for correlations.
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RESULTS
Demographics
Of 104 patients referred with problematic severe asthma, 51 were classified as having
difficult asthma (Fig 1). Fifty-three (51%) of 104 patients with true STRA were further
investigated. The clinical characteristics of subjects are shown in Table I. Forty-five (85%)
of 53 patients with STRAwere atopic compared with 7 (47%) of 15 control subjects (P <.
01). The median baseline FEV1 in patients with STRA was 68.5% (interquartile range
[IQR], 54.8% to 86.5%) of predicted value compared with 94% (IQR, 85% to 106%) in
control subjects (P < .0001).
Bronchoscopic findings
There were no complications after bronchoscopy. Findings from nonasthmatic control
subjects are listed in Table E1. Positive BAL fluid bacterial cultures were present in 10
(19%) of 53 patients with STRA, of whom 7 (70%) of 10 also had BAL fluid neutrophilia.
Positive cultures and neutrophilia were present in 2 control subjects. BAL fluid supernatants
from patients with a positive bacterial culture and neutrophilia were excluded from cytokine
analysis.
Inflammation in BAL fluid and biopsy specimens
Although BAL fluid and biopsy specimens were taken from all subjects, not all samples
were of sufficient quality for analysis. One hundred twenty-one biopsy specimens were
taken from 69 subjects, and at least 1 specimen was suitable for assessment for all subjects,
except 1 control child. Three patients with STRA and 4 control subjects only had evaluable
H&E-stained sections and therefore only had quantification of airway remodeling. The CV
for intraobserver repeatability for all biopsy specimen inflammatory cells and cytokines was
less than 10% (see Table E2 in this article’s Online Repository at www.jacionline.org). The
intraobserver repeatability for RBM thickness, epithelial shedding, and oral corticosteroid
subepithelial volume fraction of ASM indexed to subepithelial tissue (Vv) smooth muscle
were 4%, 6.4%, and 11.6%, respectively. The within-subject between-biopsy variability for
eosinophil counts was 54% (see Table E3 in this article’s Online Repository at
www.jacionline.org). However, the between-subject variation in biopsy specimen eosinophil
counts for patients with STRA was 185%.
BAL fluid was available in 50 of 53 patients with STRA and 14 of 16 control subjects (Fig
1). Children with STRA had significantly increased BAL fluid eosinophil counts compared
with those seen in control subjects (median, 2.7% [IQR, 1% to 7.7%] vs 0% [IQR, 0% to
0.9%], respectively; P <.001), although there was wide variability among patients with
STRA (Fig 2, A). Subepithelial mucosal eosinophil counts were significantly higher in
patients with STRA than in control subjects (median, 11.2/mm2 [IQR, 0-33.7/mm2] vs 0/
mm2 [IQR, 0-25.1/mm2], respectively; P < .01; Fig 2, B-D).
There were no group differences in BAL fluid neutrophil or lymphocyte counts, submucosal
neutrophil counts, mast cell counts, and CD45+, CD4+, or CD8+ cell counts (Table II).
Intraepithelial and smooth muscle inflammatory cells were similar between groups. No
associations were found between mucosal inflammation and lung function, sex, intubation
for asthma, persistent airflow limitation, gastroesophageal reflux, or serum IgE levels.
BAL fluid and sputum cytokine levels
There were no significant differences between patients with STRA and control subjects in
levels of BAL fluid IL-1β, IL-4, IL-5, IL-8, IL-13, IFN-γ, and eotaxin when measured with
the Luminex multiplex assay (see Table E4 in this article’s Online Repository at
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www.jacionline.org). A few children with STRA had detectable levels of BAL fluid IL-4 (n
= 10), IL-5 (n = 8), and IL-13 (n = 8); however, the group median value was in the
undetectable range (see Table E4). To confirm these findings, BAL fluid IL-5 and IL-13
levels were also quantified by using the Cytometric Bead Array, and again, there was no
difference between patients with STRA and control subjects (see Table E4). The limits of
detection for cytokines used in both assays are shown in Table E5 in this article’s Online
Repository at www.jacionline.org.
There was no difference in BAL fluid TH2 cytokine levels between children with persistent
symptoms and those with frequent exacerbations. However, children who had any detectable
BAL fluid TH2 cytokines (any of IL-4, IL-5, or IL-13) had significantly lower FEV1 and
forced vital capacity (FVC) percent predicted values and greater BDR than those with
undetectable TH2 cytokines (Table III).
Forty-one children underwent sputum induction, and 36 had a sufficient sample. Children
with STRA, as a group, had undetectable levels of IL-4, IL-13, and IFN-γ in sputum (see
Table E4). Eight children with STRA had detectable levels of sputum IL-5 (median, 0.9 pg/
mL [IQR, undetectable-1.0 pg/mL]).
Submucosal IL-5+ and IL-13+ cells
Tissue expression of IL-5 and IL-13 was assessed to further support findings from the BAL
fluid and sputum cytokine quantification. The intraobserver repeatability of biopsy specimen
cytokine-positive cells was less than 10%. The within-subject, between-specimen variability
for biopsy specimen IL-5 expression was 39%, and the between-subject variability in biopsy
specimen IL-5 expression for control subjects was 69%. There was a significantly higher
number of IL-5+ submucosal cells in control subjects compared with numbers seen in
children with STRA (median: STRA, 47.3/mm2 [IQR, 27.6-96.4/mm2] vs control subjects,
154.3/mm2 [IQR, 72.6-257.1/mm2]; P <.05; Fig 3, A). There were no significant differences
in numbers of submucosal IL-13+ cells between patients with STRA and control subjects
(median, 15.95/mm2 [IQR, 9.52-34.2/mm2] vs 8.58/mm2 [IQR, 2.08-102.3/mm2]),
respectively (Fig 3, B).
Relationship between IL-5 levels and eosinophilic inflammation
There was no difference in biopsy specimen, BAL fluid, or sputum eosinophil counts in
subjects with STRA in whom IL-5 was detected compared with counts in those in whom
IL-5 was undetectable (see Fig E3). Those children in whom IL-5 was detectable in sputum
had a significantly lower FEV1 than those with absent IL-5 (P < .05).
Airway remodeling
Children with STRA had increased RBM thickness compared with that seen in control
subjects (7.12 μm [IQR, 6.37-7.89 μm] vs 4.89 μm [IQR, 4.16-6.16 μm], respectively; P < .
0001; Fig 4, A). Epithelial shedding was similar in both groups (Fig 4, B). Vv was
significantly increased in patients with STRA compared with control subjects (0.20 [IQR,
0-0.65] vs 0.09 [IQR, 0-0.16]; P < .001; Fig 4, C). The subepithelial volume fraction of
ASM indexed to the surface area of RBM (Vs) was also increased in patients with STRA
compared with that seen in control subjects (19.83 [IQR, 10.85-36.93] vs 9.14 [IQR,
4.55-15.88]; P < .01;Fig 4, D).
Influence of atopy on inflammation, remodeling, and TH2 cytokines
When all subjects were compared, BAL fluid and biopsy eosinophil counts were higher in
atopic compared with nonatopic subjects. RBM thickness, epithelial shedding, and ASM Vv
were also greater in atopic compared with nonatopic children (Tables IV and V). However,
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atopic children with STRA had increased ASM mass compared with atopic control subjects
(Tables IV and V).
Influence of steroids on inflammation, remodeling, and TH2 cytokines
There was no relationship between dose of inhaled or maintenance oral steroids and any
parameters of inflammation or detection of TH2 cytokines in children with STRA (see
Tables E6 and E7 in this article’s Online Repository at www.jacionline.org). However, there
was a negative association between ASM mass and oral steroid dose (ASM Vv: r = −0.63, P
< .002; ASM Vs: r = −0.73, P < .001).
DISCUSSION
In this large pediatric bronchoscopic study, an important novel facet is the use of prior
detailed evaluation to exclude as far as possible all those who were nonadherent or had other
confounding issues. We have shown that, unlike in adults,28-30 STRA in children is
characterized by eosinophilic and not neutrophilic airway inflammation, there is no mast cell
myositis,31 and the eosinophilic inflammation is not driven by signature TH2 cytokines in
most patients.9
Quantification of BAL fluid cytokines was performed by using 2 separate assays, and levels
of TH2 cytokines remained undetectable in patients with STRA and control subjects by
using both techniques, despite the limits of detection for TH2 cytokines with both assays
being low. Indeed, the assays were sensitive enough to detect the levels of cytokines found
in studies of severe eosinophilic asthma, with a comparable degree of airway eosinophilia.32
In addition, induced sputum supernatants were analyzed because these are less dilute with
similar results. However, our sputum samples were processed with DTT, which can affect
cytokine measurements.33 Inspection of the calibration curves (see Fig E2 in this article’s
Online Repository at www.jacionline.org) showed that DTT did not affect IL-5
quantification but might have reduced the sensitivity for IL-4 and IL-13. DTT rendered
sputum eotaxin completely undetectable. Finally, to support the BAL fluid and sputum
findings, submucosal IL-5 and IL-13 expression were also quantified in biopsy specimens.
Again, no differences were found in the expression of IL-13 between patients with STRA
and control subjects, and if anything, IL-5+ cell counts were higher in control subjects.
However, the spread of data is wide (Fig 3, A) and suggests the control subjects likely
represent the normal range (because they include atopic subjects). We acknowledge that our
control subjects were having a clinically indicated bronchoscopy and were therefore
undergoing invasive procedures for significant medical problems, which might be a
confounder. However, cytokine levels were predominantly undetectable in both groups,
suggesting this confounder did not cause increases in false-positive results. Eight (15%) of
53 children with STRA had detectable levels of BAL fluid and sputum IL-5; however, even
in these children, there was no relationship between sputum, BAL fluid, or biopsy
eosinophil counts and IL-5 levels. We therefore believe that failure to detect increased TH2
cytokine levels in our patients with STRA is real because only a very small number of
children with STRA had any detectable levels in any compartment that we examined. Eight
of 20 patients with STRA with BAL fluid and sputum samples had no detectable TH2
cytokines in either. None of the patients with detectable TH2 cytokines in sputum and BAL
fluid had high tissue cytokine expression (defined as greater than the mean value for control
subjects in biopsy specimens). Even levels of IL-5, which could be reliably quantified in
BAL fluid, sputum, and biopsy specimens and is most closely related to eosinophil
recruitment, were not increased.
When we split the children with STRA into those with any detectable BAL fluid TH2
cytokines (IL-4, IL-5, or IL-13) and undetectable TH2 cytokines, the former had
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significantly lower spirometric results and greater BDR (Table III), suggesting more severe
disease. Looking for the presence of any TH2 cytokines in children with STRA might
therefore be a biomarker that allows identification of the subgroup more likely to respond to
specific antibody therapies directed against TH2 cytokines. This suggests that pediatric
STRA is heterogeneous and that treatment needs to be individualized. However, when
children with STRA were split according to clinical criteria into those with persistent
symptoms or those with frequent exacerbations, there was no difference in TH2 cytokine
levels between the 2 groups.
Another notable finding is the wide variation in BAL fluid and biopsy eosinophil counts
between subjects. Although eosinophil counts were higher in children with STRA as a group
compared with control subjects, within the group, eosinophil numbers were very different.
This finding further underscores that STRA in children is a heterogeneous disease.
It is likely that TH2 cytokines were undetectable because these children were receiving high-
dose maintenance steroids. This might not have been found in previous studies because of a
failure to address adherence adequately. Importantly, the samples were taken when the
children were receiving their usual prescribed medication but before a high-dose systemic
steroid trial, which, if given before the bronchoscopy, might otherwise have modified the
airway pathology. Although some subjects were prescribed low-dose maintenance oral
steroids at baseline, post hoc analysis showed no difference between the children who were
and were not prescribed oral steroids and no relationships between inhaled or oral steroid
dose and airway pathology. We cannot exclude the possibility that TH2 cytokines had
initiated eosinophilic inflammation in patients with STRA, but we have presented clear
evidence that these cytokines do not propagate established eosinophilic inflammation. We
believe our data suggest that the classical TH2 cytokines IL-4, IL-5, and IL-13 are steroid
sensitive and therefore undetectable and that other steroid-resistant mediators are likely
responsible for driving eosinophilic inflammation in patients with severe therapy-resistant
disease. Although IL-17 might be a candidate,34 the absence of neutrophilic inflammation
and the fact that the source or role of IL-1735 in this group is not known mean mechanisms
need to be explored in experimental models36 before being confirmed in pediatric airway
samples because only limited samples (both size and volume) can be obtained from children.
Our data have important practical implications. The anti–IL-5 mAb mepolizumab has been
shown to be beneficial in adults with persistent airway eosinophilia and multiple asthma
exacerbations.37-39 Our findings suggest that there is little indication for anti-TH2 mAb
therapy in many children with STRA. In children, at least, the presence of sputum
eosinophilia should not be uncritically assumed to be synonymous with TH2-driven
inflammation. There is a clear need to elicit the mechanism of this apparently non–TH2-
mediated airway eosinophilia to develop appropriate biological therapies in children with
severe disease.
This study includes the largest cohort of children with genuine STRA that has been
investigated invasively before a steroid trial. Previous pediatric reports have only included
patients with difficult asthma and inflammatory data after a steroid trial.1,13 This is crucial
because there is no reason to suppose a priori that airway pathology will be the same in a
patients with steroid-resistant asthma as in a child who is nonadherent to ICSs.
There are a number of limitations. The study is cross-sectional, but this is inevitable because
longitudinal invasive studies are unethical in children. Subjects with milder disease undergo
bronchoscopy rarely, and therefore the data are only applicable to children with STRA.
However, a previous study in children with mild-to-moderate asthma has shown increased
tissue expression of IL-4 and IL-5,40 which is in contrast to our findings. Also, because
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control subjects were age matched and isolated upper airway problems are less common in
school-aged children than those less than 5 years old, recruitment was difficult, and thus
numbers were small.
Atopy was not the main focus of the study because so few of the children with STRA were
nonatopic. However, increases in biopsy specimen and BAL fluid eosinophil counts,
epithelial shedding, RBM thickness, and ASM mass were present in atopic compared with
the very few nonatopic subjects, regardless of disease status. These findings are in contrast
to a previous report in children with mild-to-moderate asthma, which showed similar
pathologic changes in atopic and nonatopic subjects.40 It is possible that there is an
increased influence of atopy on pathology as disease severity increases. Importantly, the
previous report did not include atopic nonasthmatic subjects, whereas 7 of 15 of our control
subjects were atopic. When these subjects were compared with atopic patients with STRA,
we found increased BAL fluid eosinophil counts, RBM thickness, and ASM mass in
asthmatic patients.
In summary, we have shown that children with STRA have airway eosinophilia to varying
degrees without neutrophilia or increased mast cell counts. There is considerable between-
patient variability within this group. Importantly, signature TH2 cytokines were absent in the
majority of children. This report high-lights that there might be different mechanisms
driving pediatric as opposed to adult STRA and carries the implication that successful adult
therapeutic strategies should not be uncritically extrapolated to children.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
J.F. was funded by an Asthma UK Foundation Grant and a grant from the Royal Brompton & Harefield Biomedical
Research Unit. S.S. is funded by the Wellcome Trust, UK, grant no. 083586/Z/07/Z. N.R. is the recipient of a
European Respiratory Society Fellowship (no. 64) and a grant of the Swiss National Science Foundation (no.
1172/05b). The project was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal
Brompton and Harefield NHS Foundation Trust and Imperial College London.
We thank all of the patients and parents for agreeing to take part in our study. We thank Winston Banya,
statistician, for his advice, and Jackie Donovan for help with the multiplex assay. We are also grateful to our
colleagues Mark Rosenthal, Ian Balfour-Lynn, Jane Davies, and Claire Hogg for allowing us to recruit their patients
to this study.
Abbreviations used
ASM Airway smooth muscle
BAL Bronchoalveolar lavage
BDR Bronchodilator reversibility
CV Coefficient of variation
DTT Dithiothreitol
H&E Hematoxylin and eosin
ICS Inhaled corticosteroid
IQR Interquartile range
RBM Reticular basement membrane
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STRA Severe therapy-resistant asthma
Vs Subepithelial volume fraction of airway smooth muscle indexed to surface area
of RBM
Vv Subepithelial volume fraction of airway smooth muscle indexed to subepithelial
tissue
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Key messages
• Pediatric STRA is characterized by airway eosinophilia and remodeling but an
absence of the classical TH2 cytokines thought to drive allergic asthma.
• There was no neutrophilia or increase in mast cell inflammation in children with
STRA, unlike in adults.
• A small subgroup of children with STRA had detectable TH2 cytokines,
suggesting phenotypic heterogeneity in this group.
• Treatments, such as anti–IL-5 antibody, might be ineffective in many children
with STRA, and alternative mediators driving the disease need to be sought.
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FIG 1.
Flow diagram illustrating the number of children with problematic severe asthma who were
assessed and how many patients with STRA underwent invasive investigations to assess
airway pathology. FENO50, Fraction of exhaled nitric oxide at 50 mL/s.
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FIG 2.
A and B, Increased BAL fluid eosinophil (Fig 2, A) and submucosal eosinophil (Fig 2, B)
counts in children with STRA compared with those seen in control subjects. C, A 5-μm
paraffin section stained with Congo red dye showing positively stained eosinophils (black
arrows) in the submucosa of a patient with STRA compared with an absence of submucosal
eosinophils in a control subject (D; original magnification ×400).
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FIG 3.
Submucosal IL-5+ (A) and IL-13+ (B) cell counts in biopsy specimens from children with
STRA compared with control subjects. Submucosal IL-5+ cell counts were higher in control
subjects compared with those seen in patients with STRA, and levels of IL-13+ cells were
similar in both groups. Analyses were performed with the Mann-Whitney U test. ns, Not
significant.
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FIG 4.
Markers of airway remodeling showing increased RBM thickness in patients with STRA
compared with control subjects (A), similar epithelial shedding in patients with STRA and
control subjects (B), increased volume of ASM indexed to subepithelium in patients with
STRA compared with control subjects (C), and increased volume of ASM indexed to RBM
in patients with STRA compared with control subjects (D). ns, Not significant.
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TABLE I
Clinical characteristics of children with STRA and nonasthmatic control subjects
Children with STRA
(n = 53)
Control subjects
(n = 16)
Age (y) 11.97 (9.97-14.4) 10.65 (7.54-12.96)
Male sex 33/53 (62%) 8/16 (50%)
Atopy 45/53 (85%) 7/15 (47%)*
Age at first symptoms (y) 1 (0.25-2.25) —
Duration of symptoms (y) 10.1 (8.3-12.7) —
Previous intubation for asthma 11/53 (21%) —
Parental smoking 13/53 (25%) 2/9 (22%)
Percent predicted FEV1 68.5 (54.8-86.5) 94 (85-106)†
BDR (%) 15.6 (5.5-23.4) 2.5 (0-8.5)
Persistent airflow limitation 13/53 (25%) —
Total IgE (IU/mL) 386 (115-1286) 40 (14-130)
Medications
 ICS (mg/d)‡ 1.6 (0.8-1.6) —
 Maintenance oral prednisolone 24/53 (45%) —
 Long-acting β-agonist 53/53 (100%) —
 Leukotriene receptor antagonist 31/53 (58%) —
 Theophylline 12/53 (23%) —
ACT score (/25) 13 (9-17) —
FENO50 (ppb; normal, <24 ppb) 50.3 (29.3-69.7) —
Sputum eosinophils (%; normal,
 <2.5%)
7.5 (3.2-30.4) —
Values are presented as medians (IQRs).
ACT, Asthma Control Test; FENO50, fraction of exhaled nitric oxide at a flow rate of 50 mL/s.
*P < .01.
†P < .05.
‡
Budesonide equivalent dose.
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TABLE II
Airway inflammation in children with STRA compared with nonasthmatic control subjects
Cell count
Patients with
STRA (n = 53)
Control subjects
(n = 16)
P
value
BAL fluid neutrophils (%) 3.5 (2-7.2) 2.7 (1.2-7.5) .37
Biopsy specimen
 neutrophils (/mm2)
8.3 (0-26.4) 1.2 (0-20.0) .32
Biopsy specimen mast
 cells (/mm2)
45.7 (25.2-69.6) 60.5 (45.1-76.4) .20
Biopsy specimen CD45+
 cells (/mm2)
149 (3.7-419.9) 209.7 (168.8-244) .11
Biopsy specimen CD8+
 cells (/mm2)
51 (17.9-80.5) 54.8 (10.1-116.8) .60
Biopsy specimen CD4+
 cells (/mm2)
145.4 (77.0-224.5) 176.5 (23.5-259) .92
Biopsy specimen CD4/
 CD8 ratio
3.30 (1.77-5.89) 2.97 (1.86-12.43) .93
Values are presented as medians (IQRs).
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TABLE III
Clinical characteristics of children with STRA with any detectable BAL fluid TH2 cytokines (IL-4, IL-5, or
IL-13) compared with those without detectable TH2 cytokines
Detectable BAL
TH2 cytokines
(n = 15)
No detectable BAL
TH2 cytokines
(n = 8)
P
value
Age (y) 11.2 (9.4-14.4) 11.7 (10.0-12.3) .78
Steroid dose:
 Maintenance (mg/d) 6.25 (5.0-7.5) 5.6 (5.0-7.2) .80
 ICS 1.6 (1.2-1.6) 1.4 (0.9-1.6) .27
Exacerbations (in past year) 8 (4-8.5) 5 (4-10) 1.0
Admissions in past year 1.5 (0-5) 0 (0-10) .70
Percent predicted FEV1 65 (42.5-71) 91.5 (83.5-96.8) <.001
Percent predicted FVC 90 (61-99) 106 (94.5-110) .03
BDR (%) 19 (14-33) 8.1 (3.6-17.4) .03
ACT score (/25) 10 (8-17) 13.5 (8-16.5) .47
BMI (kg/m2) 17.6 (16.1-18.6) 23.8 (21-28) .009
BMI percentile 66 (22-78) 99 (96-99.7) .005
Values are presented as medians (IQRs). Boldface text indicates statistically significant results.
ACT, Asthma Control Test; BMI, body mass index; FVC, forced vital capacity.
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